Agios Pharmaceuticals: D. E. Shaw reports 6.5% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Agios Pharmaceuticals, Inc. (AGIO) is the issuer whose common stock D. E. Shaw & Co., L.P. and David E. Shaw each report beneficial ownership of 3,888,907 shares, equal to 6.5% of the class. The amendment identifies September 30, 2026, as the event date. The reporting persons report shared voting power over 3,607,007 shares and shared dispositive power over 3,888,907 shares, with no sole voting or dispositive power. David E. Shaw states that he owns no shares directly and disclaims beneficial ownership.
Key Figures
Key Terms
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.